Trial Profile
A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Alrizomadlin (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Appendiceal cancer; Carcinoma; Liposarcoma; Lung cancer; Malignant melanoma; Nerve sheath neoplasms; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Urogenital cancer; Uveal melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms Keynote MK-3475-B66
- Sponsors Ascentage Pharma
- 30 Jan 2024 Planned End Date changed from 30 Mar 2024 to 30 Mar 2025.
- 30 Jan 2024 Planned primary completion date changed from 30 Dec 2023 to 30 Dec 2024.
- 06 Jun 2023 Preliminary results(n=24) assessing safety and efficacy of alrizomadlin in combination with pembrolizumab for treatment of patients with malignant peripheral nerve sheath tumor presented at the 59th Annual Meeting of the American Society of Clinical Oncology